Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

Tabuk obatined rights to commercialise Formosacs l'obetasol propionate ophthalmic suspension 0.05% for inflammation after ocular surgery.

May 11, 2024 - 04:00

Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension

Tabuk obatined rights to commercialise Formosacs l'obetasol propionate ophthalmic suspension 0.05% for inflammation after ocular surgery.

Read the original article

Tags:

Previous Article

Shionogi secures licence for Maze’s Pompe disease treatment

Four ways the vaccine rush will define infectious disease trends for CROs in 2024

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Bupa is leveraging its unique position to develop IoT and AI features

Bupa is leveraging its unique position to develop IoT a...

Jan 17, 2024

OCX-063 by OccuRx for Proliferative Vitreoretinopathy (...

Jun 5, 2023

Novartis’ urticaria drug meets all endpoints in Phase III trials

Novartis’ urticaria drug meets all endpoints in Phase I...

Nov 12, 2023